BioWorld

June 2, 2004

Pozen's Second Migraine Drug, MT 100, Turned Down By FDA

Pozen Inc.'s stock plummeted Tuesday on news that it received a not-approvable letter from the FDA for its migraine drug MT 100. (BioWorld Today) Read More

$180M Stock-Swap Merger Joins Aclara With ViroLogic

SuperGen Submits First Part Of Rolling NDA For Dacogen

ARYx Raises $55M To Fund Development Of Safer Drugs

Serono Starts Phase III Trial Of Serostim In HARS Patients

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for Jan 15, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Jan. 15, 2026.

3D rendering of antibody drug conjugated with cytotoxic payload

ADCs’ breakout 2025 and their still-unfinished potential

BioWorld

Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...

LINC01116 has prognostic value in lung cancer, study shows

BioWorld MedTech

Long noncoding RNAs (lncRNAs) have emerged as potential markers of disease, since they associate with proteins that regulate gene expression, translation or...

SERPINB1 as potential biomarker for spinocerebellar ataxia type 2

BioWorld Science

Researchers from Goethe-Universität and collaborators investigated novel molecular biomarker candidates for spinocerebellar ataxia type 2, a progressive...